Summary by Moomoo AI
The Vanguard Group has filed an amended Schedule 13G/A with the Securities and Exchange Commission on February 13, 2024, indicating a change in their holdings of Merck & Co Inc. As of December 29, 2023, The Vanguard Group reported a 9.66% ownership stake in Merck & Co, with an aggregate amount of 244,767,034 shares beneficially owned. This includes shared voting power over 3,215,979 shares and sole dispositive power over 233,574,886 shares, with an additional shared dispositive power over 11,192,148 shares. The filing was made under Rule 13d-1(b) of the Securities Exchange Act of 1934, which is typically used by passive investors. The Vanguard Group, based in Pennsylvania, is an investment adviser and reports that the securities were acquired in the ordinary course of business, not with the purpose of changing or influencing the control of the issuer.